论文部分内容阅读
目的 设计特异性耐受原 ,通过其鼻黏膜耐受治疗对实验性自身免疫性重症肌无力 (EAMG)发病过程的影响 ,以探讨该疗法在模型应用中的可行性。方法 用 Lewis大鼠建立 EAMG模型 ,选取双类似物作为耐受原在致敏同时给予鼻黏膜耐受治疗 ,动态观察大鼠体重及临床评分改变。结果 虽然治疗组大鼠发病率不降低 ,但是在 EAMG急性期和慢性期 ,其临床症状均较对照组减轻 (P <0 .0 5 )。结论 用双类似物鼻黏膜耐受可以达到治疗 EAMG的目的 ,其结果为抗原特异性治疗重症肌无力 (MG)和其他自身免疫性疾病 (AID)提供了依据。
Objective To design the effect of specific tolerogenic therapy on the pathogenesis of experimental autoimmune myasthenia gravis (EAMG) through its nasal mucosal tolerance therapy and to explore the feasibility of this therapy in the model application. Methods The Lewis rats were used to establish EAMG model. Two analogs were selected as tolerogenic agents for nasal mucosal tolerance. Dynamic changes of body weight and clinical scores were observed. Results Although the incidence of rats in the treatment group did not decrease, the clinical symptoms in the acute and chronic EAMG patients were lower than those in the control group (P <0.05). Conclusions The nasal mucosal tolerance with dual analogues can achieve the purpose of treating EAMG. The results provide the basis for antigen-specific treatment of myasthenia gravis (MG) and other autoimmune diseases (AIDs).